[LCID Study Number: 20193055]
EA5163/S1709 INSIGNA: A Randomized, Phase III Study of Firstline Immunotherapy Alone or in Combination With Chemotherapy in Induction/Maintenance or Postprogression in Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC) With Immunobiomarker SIGNature-Driven Analysis
The purpose of this study is to see if starting treatment with the immunotherapy drug, MK-3475 (pembrolizumab), alone, instead of a combination of immunotherapy and chemotherapy, will result in a significant improvement in overall survival (OS) (time being alive).
Disease/Condition: Non-Small Cell Lung Cancer
Department: Hematology and Oncology
Location(s): Lahey Hospital & Medical Center (Burlington); Lahey Medical Center, Peabody; Winchester Hospital
Primary Contact Email: [email protected]
Primary Contact Phone: 781-744-3421